Trial · NCT07595237
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose-limiting toxicity(DLT) of the single dose | 4 to 6weeks | Occurance of DLT in the first cycle of each group |
| Primary | The safety and tolerance of 177Lu-DOTA-SNA040 | 4 to 6 weeks | The occurance and stage of AE and SAE according to CTCAE |
| Primary | The safety and tolerance of 177Lu-DOTA-SNA040 | 4 to 6 weeks | The rates of abnormal laborotary tests after administration |
| Primary | The safety and tolerance of 177Lu-DOTA-SNA040 | 4 to 6 weeks | The rates of abnormal vital signs after administration |
| Primary | The safety and tolerance of 177Lu-DOTA-SNA040 | 4 to 6 weeks | The rates of abnormal physical examination after administration |
| Primary | The safety and tolerance of 177Lu-DOTA-SNA040 | 4 to 6 weeks | The rates of abnormal 12-lead ECG after administration |
| Secondary | The biodistribution of SNA040 | 1 week | Absorbed dose in major organs throughout the body (red bone marrow, kidneys, liver, intestines, etc.) |
| Secondary | The tumor uptake of SNA040 | 1 week | SUVmax and SUVmean of tumor |
| Secondary | The tumor uptake of SNA040 | 1 week | The retention time of tumor |
| Secondary | The tumor uptake of SNA040 | 1 week | The ID% of tumor |
| Secondary | To evaluate the radiological characteristics 177Lu-DOTA-SNA040 | 1 week | Rradiation doses in whole blood, serum, urine measured using a gamma counter |
| Secondary | The pharmacokinetic of the SNA040 protein | 1 week | Peak plasma concentration (Cmax) of the SNA040 |
| Secondary | The pharmacokinetic of the SNA040 protein | 1 week | Area under the concentration-time curve (AUC) of the SNA040 |
| Secondary | The pharmacokinetic of the SNA040 protein | 1 week | Clearance (CL) of the SNA040 |
| Secondary | Assessment of the immunogenicity of SNA040 | 1 week | Occurance of positive immunogenicity test |
| Secondary | Assessing tumour response according to RECIST1.1 | 4 to 6 weeks | The DCR of tumors |
| Secondary | Assessing tumour response according to RECIST1.1 | 4 to 6 weeks | The ORR of tumors |
| Secondary | Assessing tumour response according to RECIST1.1 | 4 to 6 weeks | The DOR of tumors |
| Secondary | Explore the PFS of subjects | 2 years | PFS according to the RECIST1.1 |
| Secondary | Explore the OS of subjects | 2 years | Overall survival (OS) according to the RECIST1.1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07595237/registered